Genprex (NASDAQ:GNPX) Cut to “Hold” at ValuEngine

ValuEngine cut shares of Genprex (NASDAQ:GNPX) from a buy rating to a hold rating in a research note published on Thursday morning, ValuEngine reports.

Other research analysts have also recently issued reports about the company. Alliance Global Partners started coverage on Genprex in a research note on Wednesday, April 22nd. They set a buy rating for the company. Noble Financial reissued a buy rating and set a $5.00 target price on shares of Genprex in a research note on Tuesday, May 26th.

GNPX opened at $3.03 on Thursday. Genprex has a 12 month low of $0.23 and a 12 month high of $7.03. The business has a fifty day moving average price of $3.02 and a 200 day moving average price of $2.33.

Genprex (NASDAQ:GNPX) last released its earnings results on Thursday, May 14th. The company reported ($0.20) EPS for the quarter. As a group, research analysts forecast that Genprex will post -0.05 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in GNPX. Renaissance Technologies LLC boosted its position in shares of Genprex by 192.6% during the 4th quarter. Renaissance Technologies LLC now owns 200,709 shares of the company’s stock worth $64,000 after acquiring an additional 132,121 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Genprex during the 1st quarter worth about $60,000. Frontier Wealth Management LLC acquired a new position in shares of Genprex during the 1st quarter worth about $41,000. Mid Atlantic Financial Management Inc. ADV acquired a new position in shares of Genprex during the 1st quarter worth about $38,000. Finally, IHT Wealth Management LLC acquired a new position in shares of Genprex during the 1st quarter worth about $100,000. 2.59% of the stock is owned by institutional investors and hedge funds.

About Genprex

Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.

Further Reading: Portfolio Manager

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.